So sánh phương pháp
Xem các phương pháp đã chọn cạnh nhau; những hàng khác biệt được làm nổi bật.
| Thang đo Đánh giá Chức năng Bệnh xơ cứng teo cơ một bên Cải tiến (ALSFRS-R)× | Thang đo Mức độ đi lại trong Đa xơ cứng-12 (MSWS-12)× | |
|---|---|---|
| Lĩnh vực | Thần kinh học | Thần kinh học |
| Họ | Process / pipeline | Process / pipeline |
| Năm ra đời≠ | 1999 | 2003 |
| Người khởi xướng≠ | James M. Cedarbaum, NIH/NINDS | Jeremy C. Hobart, University of Plymouth |
| Loại≠ | Clinician-rated and patient-reported hybrid | Self-report questionnaire |
| Công trình gốc≠ | Cedarbaum, J. M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., & Nakanishi, A. (1999). The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. Journal of the Neurological Sciences, 169(1-2), 13-21. DOI ↗ | Hobart, J. C., Riazi, A., Lamping, D. L., Fitzpatrick, R., & Thompson, A. J. (2003). Measuring the impact of MS on walking ability: The 12-Item MS Walking Scale (MSWS-12). Neurology, 60(1), 31-36. DOI ↗ |
| Tên gọi khác | ALS FRS-R, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised | MS Walking Scale-12, MSWS |
| Liên quan≠ | 4 | 3 |
| Tóm tắt≠ | The ALSFRS-R is a 12-item clinician-administered functional rating scale designed to assess disease progression and functional status in amyotrophic lateral sclerosis (ALS). Introduced by Cedarbaum and colleagues in 1999, it expands upon the original ALSFRS by incorporating respiratory function assessment. It is the primary outcome measure in ALS clinical trials and routine clinical monitoring, providing quantitative tracking of disease decline that predicts survival and guides management decisions. | The MSWS-12 is a brief, patient-reported outcome measure specifically designed to assess the impact of multiple sclerosis on walking ability and limitation. Developed by Hobart and colleagues in 2003, this 12-item scale captures both the physical difficulty and functional consequences of MS-related gait impairment. It is highly responsive to change and widely used in MS clinical trials and practice as a primary outcome measure for assessing intervention effects on mobility. |
| ScholarGateBộ dữ liệu ↗ |
|
|